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Antimicrobial resistance (particularly by extended spectrum -lactamase and aminoglycoside 25 
modifying enzyme production) in neonatal sepsis is a global problem, particularly in low- and 26 
middle-income countries, causing significant mortality. High rates of resistance are reported for 27 
the current WHO-recommended first-line antibiotic regimen for neonatal sepsis; ampicillin and 28 
gentamicin. We assessed the utility of fosfomycin and amikacin as a potential alternative 29 
regimen to be used in settings of increasingly prevalent antimicrobial resistance.  30 
The combination was studied in a 16 arm dose ranged hollow-fiber infection model (HFIM) 31 
experiment. The combination of amikacin and fosfomycin enhanced bactericidal activity and 32 
prevented emergence of resistance compared to monotherapy of either antibiotic. Modelling 33 
of the experimental quantitative outputs and data from checkerboard assays, indicated 34 
synergy. 35 
We further assessed the combination regimen at clinically relevant doses in HFIM with nine 36 
Enterobacterales strains with high fosfomycin/amikacin MICs and demonstrated successful kill 37 
to sterilisation in 6/9 strains. From these data, we propose a novel combination breakpoint 38 
threshold for microbiological success for this antimicrobial combination against 39 
Enterobacterales - MICF  * MICA < 256 (where MICF and MICA are MICs for fosfomycin and 40 
amikacin). Monte Carlo simulations predict that a standard fosfomycin/amikacin neonatal 41 
regimen will achieve a >99% probability of pharmacodynamic success for strains with MICs 42 
below this threshold.  43 
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We conclude that the combination of fosfomycin with amikacin is a viable regimen for the 44 
empiric treatment of neonatal sepsis and is suitable for further clinical assessment in a 45 
randomised controlled trial.  46 
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Introduction  47 
Neonatal sepsis is a common condition with a high mortality (1).  Leading causative pathogens 48 
are both Gram-negative (e.g. E. coli, K. pneumoniae) and Gram-positive organisms (e.g. 49 
Staphylococcus aureus, Streptococcus agalactiae (Group B streptococci - GBS))  (1).  Neonatal 50 
sepsis accounts for an estimated 430,000 - 680,000 deaths annually, with the highest mortality 51 
in low- and middle-income countries (LMICs) (2, 3).  The World Health Organisation (WHO) 52 
currently recommends a narrow-spectrum β-lactam agent (e.g. amoxicillin or penicillin G) in 53 
combination with gentamicin as the first line empiric regimen to treat neonatal sepsis (4, 5).  54 
This regimen has an acceptable safety profile, is active against common causative wild-type 55 
organisms, is inexpensive and feasible to administer.  However, clinical efficacy is increasingly 56 
compromised by the rise of antimicrobial resistance (AMR). 57 
Multiple epidemiological studies of neonatal sepsis demonstrate significant levels of drug 58 
resistance, particularly to -lactams and gentamicin (6–12), with a variety of increasingly 59 
prevalent resistance mechanisms such as extended spectrum -lactamases (ESBLs) and 60 
aminoglycoside modifying enzymes (AMEs). In hospital settings, resistance rates of Gram-61 
negative bacteria causing neonatal sepsis to amoxicillin and gentamicin are approximately 80% 62 
and 60%, respectively, with some regional variation (6–12).  Alternative options are urgently 63 
required for the treatment of neonatal sepsis caused by multi- and extremely-drug resistant 64 
(MDR and XDR) bacteria and suitable for use in LMIC settings. 65 
A potential replacement regimen would need to provide spectrum of activity against the 66 
commonly encountered pathogens and resistance motifs. Additionally, if the regimen were a 67 
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combination of two agents, a favourable pharmacodynamic interaction would benefical. 68 
Antimicrobial interactions can be defined by several metrics and definitions (13). However, the 69 
interaction model described by Greco based on Loewe additivity (14, 15) allows determination 70 
and quantification of any interaction with precision and without arbitrary thresholds for 71 
determining the natures of interaction. 72 
Amikacin and fosfomycin have several attributes that make them potential candidates for use 73 
in neonatal sepsis.  They are off-patent with a neonatal licence, have an acceptable safety 74 
profile with limited toxicities (16, 17), and have efficacy against commonly encountered 75 
multidrug resistant (MDR) pathogens. We therefore studied the potential utility of this 76 
combination for neonatal sepsis by assessing in vitro activity, the nature and extent of any 77 
pharmacodynamic interaction using checkerboard assays and hollow fiber infection models 78 
(HFIMs), and defined candidate combination regimens suitable for further clinical study.  79 
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In vitro susceptibility testing 81 
A panel of 40 strains of bacterial species was assembled to give a representative range of 82 
bacteria that cause neonatal sepsis in a LMIC setting, with a majority of strains harbouring 83 
relevant resistance motifs for geographic regions of interest. These include 10 methicillin-84 
resistant Staphyloccocus aureus (MRSA) strains, 10 E. coli and 10 K. pneumoniae strains (all ESBL 85 
or carbapenemase producers), and 10 wild-type S. agalactiae strains (Table S1).  The MIC 86 
distributions for fosfomycin and amikacin against this panel of strains are shown in Table S2. 87 
The modal amikacin MIC was 2-4 mg/L (excluding the intrinsically resistant S. agalactiae, 88 
inhibited by a modal MIC of >32 mg/L); the modal fosfomycin MIC was 2 mg/L (excluding the K. 89 
pneumoniae strains, which have a modal MIC of >32mg/L, likely due to a high incidence of 90 
chromosomal FosA (18)).  91 
 92 
In vitro drug-drug interaction modelling 93 
Checkerboard assays were performed on a selection of the neonatal sepsis panel strains (n=16). 94 
These strains were selected on the basis of having MICs >0.0625mg/L and <32mg/L for 95 
fosfomycin and amikacin. An interaction model originally developed by Greco (14) was fitted to 96 
the dataset to estimate a pharmacodynamic interaction parameter, , for each strain (Fig. 1). A 97 
value of  for the interaction of two agents is interpreted as follows: a lower bound of the 95% 98 
CI of  > 0 indicates a synergistic interaction; an upper bound of the 95% CI of  < 0 indicates an 99 
antagonistic interaction; a 95% CI crossing 0 indicates no evidence of interaction i.e. simple 100 
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additivity (14)). A total of 9/16 individual strains had CIs >0 (and therefore indicated synergy); 101 
the remaining 7/16 strains had CIs crossing 0 (and therefore demonstrated no evidence of 102 
interaction). When the  value output of the models fitted to each strains were combined in a 103 
meta-analysis, the combined  interaction value was 0.1705 (95% CI 0.0811 to 0.2599), with 104 
low inter-strain heterogeneity (I2 = 30.7%, p value = 0.383) indicating a synergistic effect 105 
observed across all species/strains tested. 106 
 107 
Pharmacodynamic interaction of fosfomycin and amikacin using neonatal PK 108 
To determine the nature and magnitude of the pharmacodynamic interaction between 109 
fosfomycin and amikacin using neonatal concentration-time profiles, a hollow fiber infection 110 
model (HFIM) was used (Fig. S1) using the E coli ST195 strain, a CTX-M-14 producer from Laos 111 
(amikacin MIC 4 mg/L; fosfomycin MIC 1 mg/L) (19) . These experiments were conducted 112 
following preliminary dose-finding experiments with each drug alone to define informative 113 
parts of the drug exposure-response and drug exposure-emergence of resistance relationships. 114 
For fosfomycin, the EC20, EC50, and EC80 for bactericidal effect were achieved with fAUC0-24 of 115 
25, 200 and 400 mg*h/L, respectively. For amikacin, the EC20, EC50, and EC80 were achieved with 116 
fAUC0-24 of 50, 200 and 380 mg*h/L, respectively.  117 
The pharmacodynamics of the fosfomycin-amikacin combination was determined in a 16-arm 118 
4x4 experiment that included no-treatment controls, each drug alone at the three doses, and 119 
an interaction matrix of all 2-drug dose combinations as shown in Fig. 2.  When administered 120 
alone, increasing fosfomycin exposures resulted in profound early bacterial killing. However, 121 
 on M





















failure to achieve sterility led to rapid regrowth, with emergence of a resistant clone(s) with 122 
fosfomycin MICs of 128mg/L, with maximal emergent resistance at fAUC0-24 of 50 and 200 123 
mg*h/L (Fig. 2, Panels 1-4).  Similarly, progressively increasing exposures of amikacin as 124 
monotherapy led to initial suppression of logarithmic growth with subsequent exposure-125 
dependent emergence of a resistant subpopulation with amikacin MICs 16mg/L, with maximal 126 
emergent resistance at fAUC0-24 of 380 mg*h/L (Fig. 2, Panels 1,5, 9, & 13). 127 
In combination, fosfomycin and amikacin achieved a greater magnitude of initial bacterial kill, 128 
with delayed and reduced emergence of resistance to fosfomycin and amikacin, compared with 129 
equivalent drug exposures in monotherapy. Higher combination exposures achieved sterility. 130 
The relationship between drug exposure and the emergence of resistance with each drug 131 
administered alone formed an ‘inverted U’ (20). Fosfomycin and amikacin in combination 132 
resulted in the suppression of resistance that occured at comparable drug exposures in 133 
monotherapy of each drug (Fig. 2, Panels 11,12 & 14-16).  As the exposure of the other 134 
antibiotic increased, the ‘inverted U’ shifted to the left as emergence of resistance was 135 
progressively suppressed (Fig. 3). 136 
The nature and magnitude of the pharmacodynamic interaction between fosfomycin and 137 
amikacin was estimated by fitting a pharmacodynamic interaction model to the PK-PD data 138 
(Table 1). The R-squared values for the observered vs individual predicted values were 0.875 139 
(free fosfomycin concentrations), 0.963 (free amikacin concentrations), 0.869 (total bacterial 140 
count), 0.944 (fosfomycin-resistant bacterial count) and 0.669 (amikacin-resistant bacterial 141 
count). There were synergistic relationships for the effects of the combination on susceptible, 142 
fosfomycin-resistant, and amikacin-resistant bacteria with  values of 13.046 [95% CI 0.761 – 143 
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25.331], 20.520 [95% CI 11.727 – 29.313], and 25.227 [95% CI 14.485 – 35.969], respectively.  144 
Hence, the combination of fosfomycin and amikacin was synergistic in terms of killing both 145 
drug-susceptible and -resistant subpopulations.  146 
 147 
Assessment of a Neonatal Combination Regimen of Fosfomycin and Amikacin 148 
We assessed the pharmacodynamics of the combination of fosfomycin and amikacin using 149 
neonatal concentration-time profiles of each drug over a 7 day period. For amikacin, we used a 150 
standard neonatal dose of 15 mg/kg q24h (21) and a median neonatal half-life of 7 hr (22). For 151 
fosfomycin we used a neonatal dose of 100mg/kg q12h with a half-life of 5.2 hr, based on 152 
preliminary data from the NeoFosfo trial (23). We selected nine Gram-negative bacteria as the 153 
challenge strains that had a range of MICs to both drugs and had different mechanisms of 154 
resistance (Table 2).  We successfully recapitulated the target free drug PK profiles associated 155 
with each regimen (data not shown).   156 
The summary pharmacodynamics are shown in Fig. 4 (full pharmacodynamic output are shown 157 
in Fig. S2-10). When administered alone, amikacin and fosfomycin failed to achieve extinction in 158 
9/9 and 7/9 strains, respectively.  All arms with strains inhibited by fosfomycin MICs >4mg/L 159 
treated with fosfomycin monotherapy had rapid emergence of resistance within 24h. The three 160 
strains inhibited by fosfomycin MICs 4mg/L were either killed to sterility (two strains) or had 161 
delayed emergence of resistance towards the end of the experiment. In contrast, the 162 
combination regimen achieved extinction in 6/9 strains. The strains for which the combination 163 
failed were all inhibited by MICs  32mg/L and  8mg/L for fosfomycin and amikacin, 164 
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respectively.  The distribution of combined fosfomycin and amikacin MICs versus response is 165 
shown in Fig. 4a. In this figure, a plane (or line) delineated two groups of strains, defined by the 166 
fosfomycin/amikacin MICs, that predicted success (defined as sterility at the end of the 167 
experiment) and failure. This ‘breakpoint plane’ was described in the following Cartesian format 168 
𝑀𝐼𝐶𝐴 ∗ 𝑀𝐼𝐶𝐹 = 256, where MICA and MICF are amikacin and fosfomycin MICs, respectively.  In 169 
a clinical context, this means that if the product of the amikacin and fosfomycin MICs inhibiting 170 
a bacterial pathogen is < 256, then treatment with a neonatal regimen of fosfomycin and 171 
amikacin in combination can be predicted to succeed (i.e. the bacterium is ‘sensitive’ to this 172 
combination). 173 
The amikacin/fosfomycin combination success data can also be arranged according to the 174 
fAUC:MIC ratio for each drug, as shown in Fig. 4b, with a similar plane describing the threshold 175 
for successful treatment with the combination. This target plane can be described with the 176 
form (𝑓𝐴𝑈𝐶𝐹/ 𝑀𝐼𝐶𝐹) ∗ (𝑓𝐴𝑈𝐶𝐴/ 𝑀𝐼𝐶𝐴)  = 2709.5 (where F and A subscripts denote 177 
fosfomycin and amikacin fAUCs and MICs respectively).  Interpreted in a clinical context, if the 178 
product of the amikacin and fosfomycin fAUC:MIC ratios is >2709.5, then the target for 179 
pharmacodynamic success has been met, with predicted treatment success. 180 
 181 
Monte Carlo Simulations 182 
Amikacin and fosfomycin fAUCs  for 10,000 neonates were created using a Monte Carlo 183 
simulation from a neonatal fosfomycin model that included neonatal covariate distributions 184 
based on a neonatal cohorts from the NeoFosfo trial and a recently completed global neonatal 185 
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sepsis observational study (NeoOBS) (23, 24) and a recently published neonatal amikacin model 186 
(25). Simulated dosing regimes were fosfomycin 100mg/kg q12 for neonates 7 days old and 187 
150mg/kg q12 for neonates >7 days, as suggested by the NeoFosfo trial results and the EMA 188 
dosing recommendations (23, 26). Simulated amikacin dosages were 15mg/kg q24 for all 189 
neonates > 2kg; neonates weighing  2kg were dosed at q48 if 7 days old and q36 if >7 days 190 
old (27).  191 
Using the target relationships defined above, we calculated a combined probability of 192 
pharmacodyamic target attainment for both drugs across MIC ranges (1 – 256 mg/L) (Table 3). 193 
These simulated fAUCs demonstrated 99% predicted target attainment for Enterobacterales 194 
with amikacin and fosfomycin MICs below the ‘breakpoint plane’.  This indicates a high 195 
likelihood that fosfomycin and amikacin in combination at the simulated dosing regimens (i.e. 196 
at standard neonatal doses) will successfully treat neonatal sepsis caused by these pathogens.  197 
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In both static and dynamic in vitro pharmacological models there was unequivocal synergistic 199 
interactions between amikacin and fosfomycin when measuring by bactericidal killing and the 200 
prevention of emergence of antimicrobial resistance. In particular, the addition of increasing 201 
doses of the second agents suppresses the ‘inverted U’ of antimicrobial resistance emergence 202 
(20) (Fig. 3) preventing the resistance observed at equivalent doses in monotherapy. These 203 
characteristics are unaffected by the presence of resistance mechanisms that render first line 204 
agents ineffective (e.g. ESBL and AMEs) in the bacteria tested in our experiments. The 205 
combination fosfomycin and amikacin is therefore a potentially useful regiment for empiric 206 
treatment of neonatal sepsis in the context of high prevalence of these resistance mechanisms 207 
Prediction of antimicrobial success has traditionally been conceived using breakpoint 208 
thresholds on a scale of a single drug concentration, with the treatment success dependent 209 
upon the bacteria being inhibited by a MIC being above or below a certain threshold on this 210 
scale. Our data suggests that using conventional monotherapy breakpoints is of limited value in 211 
combination antibiotics (Fig. 4). Here, we propose a novel two-dimensional breakpoint 212 
concentration threshold for treatment success defined by the Cartesian function of the 213 
pathogen’s fosfomycin and amikacin MIC; 𝑀𝐼𝐶𝐴 ∗ 𝑀𝐼𝐶𝐹 = 256, where A and F subscripts 214 
denote amikacin and fosfomycin MICs respectively.  Enterobacterales pathogens that are 215 
inhibited by amikacin and fosfomycin MICs lying beneath this threshold (i.e. MICA*MICF < 256) 216 
can be predicted to be successfully treated by the standard regimen of these agents used in 217 
neonates i.e. it is specific to a neonatal context. 218 
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In a further extension, we also propose a novel combination pharmacodynamic target threshold 219 
for the combination regimen for predicted treatment success, described in the following 220 
Cartersian format: (𝑓𝐴𝑈𝐶𝐹/ 𝑀𝐼𝐶𝐹) ∗ (𝑓𝐴𝑈𝐶𝐴/ 𝑀𝐼𝐶𝐴)  = 2709.5.  The probabilities of standard 221 
neonatal regimens of these drugs attaining this threshold, for bacteria inhibited by a range of 222 
MIC combinations and incorporating the variability of neonatal drug exposure, are summarised 223 
in Table 3.  224 
We aimed to ensure a diversity of resistance mechanisms across the strains used, with 225 
commonly encountered resistance motifs in LMICs represented, acknowledging we are limited 226 
to the nine strains used. Whilst it is possible that bacteria with resistance mechanisms not 227 
examined in our experiments do not follow the relationship described, the MIC provides an 228 
integrative measure of potency regardless of the molecular mechanism of resistance, and can 229 
be used to predict pharmacodynamic response, as with conventional breakpoints.  230 
In our HFIM experiments the monotherapy arms failed with strains inhibited by fosfomycin and 231 
amikacin MICs below their EUCAST breakpoint concentrations (32mg/L for fosfomycin and 232 
8mg/L for amikacin (28)). The underperformance of amikacin partially supports the recent 233 
downward revision of aminoglycoside breakpoint concentrations by EUCAST with a 234 
recommendation to avoid aminoglycoside monotherapy for systemic infections (28), but also 235 
reflects the observed greater tendency of aminoglycoside exposure to generate emergence of 236 
resistant small-colony variants in vitro than is observed in vivo (29). Failure of fosfomycin as 237 
monotherapy for strains inhibited by MICs >4mg/L supports suggestions that the breakpoint 238 
concentration for neonatal systemic infections should be lower than the currently stated 239 
EUCAST breakpoint for adult systemic infections of 32mg/L (28) (as has previously also been 240 
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suggested in an adult context too (30)). However, the ideal breakpoint concentration for 241 
fosfomycin alone is difficult to define because this agent should not be used as monotherapy 242 
due to potential for rapid emergence of resistance (31, 32). 243 
There is an increasing number of experimental models of neonatal infection and sepsis (33, 34). 244 
HFIMs has been previously used to explore the pharmacodynamics of vancomycin and 245 
teicoplanin for neonatal sepsis (33, 35).  HFIM has the advantage of enabling the simulation of 246 
neonatal pharmacokinetics to explore drug exposure effect and drug exposure resistance 247 
relationships that are specific to this special population. This is extremely difficult to achieve in 248 
laboratory animal models, due to inherent pharmacokinetic differences with humans.  249 
Furthermore, laboratory animal models of bacteraemia have additional difficulties in 250 
establishing pharmacodynamic relationships to due to the relatively low and intermittently 251 
detectable bacterial densities.  The HFIM overcomes these limitations.   252 
However, the HFIM does not replicate the anatomical barriers that may be important for 253 
infections of the lung and brain, and does not contain any immunological effectors (even if 254 
these are immature in neonates) that may contribute to antimicrobial activity. Furthermore, 255 
the relatively high density of the inoculum used in HFIM to ensure reproducible results (circa. 256 
106 cfu/mL) is higher than the estimates for the bacterial density in the bloodstream of 257 
neonates with sepsis (circa. 100-103 CFU/mL) (36, 37). For these reasons, the conclusions from 258 
the HFIM may be conservative and represent a worst-case scenario for regimen identification.  259 
Furthermore, the conclusions of these experiments are applicable only to the treatment of 260 
systemic infections (i.e. neonatal sepsis) given the replication of neonatal systemic drug 261 
exposures. Whilst both amikacin and fosfomycin have a degree of CSF penetration (amikacin 262 
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has a CSF partition coefficient of 0.1 in neonates (38); fosfomycin has a CSF coefficient of 0.15-263 
0.2 in adults (39), with neonatal data expected in the Neofosfo trial (23)), the CSF drug 264 
exposures and the behaviour of bacterial inoculums in neonatal meningitis will be different to 265 
those modelled in this system. 266 
Despite these limitations, we conclude these experiments demonstrate that the regimen of 267 
fosfomycin and amikacin in combination is synergistic in both bactericidal effect and prevention 268 
of acquired antimicrobial resistance to either drug, with a defined threshold for probable 269 
treatment success. Additionally both agents have attributes that make them suitable for use in 270 
LMIC settings: i) Stability at room temperature (40, 41); ii) Ease of administration with once or 271 
twice daily dosing; iii) Minimal toxicities; iv) Off-patent status, and therefore potential 272 
affordability; v) Potential activity, in combination, to the predominant bacterial causes of 273 
neonatal sepsis. We conclude that this combination regimen could be considered appropriate 274 
for empiric treatment of neonatal sepsis in LMIC settings.  275 
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Methods and Materials 276 
Antimicrobial agents. Amikacin (Alfa Aesar, Haverhill), and fosfomycin (Sigma-Aldrich, St Louis) 277 
were purchased.  Both agents were stored at 2-8oC in anhydrous form.  Fresh solutions were 278 
prepared in sterile distilled water prior to any use.  For the in vitro hollow fiber infection model 279 
(HFIM) experiments, a licensed pharamaceutical preparation of fosfomycin (Fomicyt, Kent 280 
Pharmaceuticals Ltd) were used and were prepared using sterile distilled water. 281 
Media and agar. Cation-adjusted Muller Hinton broth (MHB) (Sigma-Aldrich, St Louis) was used 282 
as the primary media in all experiments. As fosfomycin requires the presence of glucose-6-283 
phosphate (G6P) for bacterial cell entry (42)  the MHB was supplemented with 25mg/L G6P 284 
(Sigma-Aldrich, St Louis) in experiments where fosfomycin is used. Mueller Hinton agar (MHA) 285 
was used in all agar plates. Commercially pre-prepared 20mL round MHA plates (Fisher 286 
Scientific, Waltham) or self-prepared 50ml square MHA plates (MHA from Sigma-Aldrich; 287 
square plates from VWR, Radnor) were used in all experiments. For drug-containing plates, 288 
MHA was supplemented with antibiotic (with 25mg/L G6P in the case of fosfomycin) and 289 
prepared within each antibiotic’s stability limits. Drug concentrations in agar were four times 290 
the MIC of the specific bacterial strain used in a given experiment. 291 
Bacterial Isolates. Isolates were supplied by JMI, IHMA, Public Health England (PHE), LGC  292 
standards, University of Birmingham, University of Oxford, and Royal Liverpool University 293 
Hospital. For the initial non-dynamic in vitro experiments, a collection of strains was collated 294 
representing a range of common possible neonatal sepsis bacterial pathogens and resistance 295 
mechanisms in an AMR prevalent environment. In total, this included 10 strains of each of the 296 
following: Group B streptococci, methicillin resistant Staphylococcus aureus (MRSA), Escherichia 297 
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coli, and Klebsiella pneumoniae. All of the Gram-negative bacteria were extended spectrum -298 
lactamase (ESBL) (nine E. coli and nine K. pneumoniae strains) or carbapenemase producers 299 
(one E. coli and one K. pneumoniae strain). Some of these strains were used in the HFIM based 300 
on their MICs, including a further two K. pneumoniae and one E. coli (ESBL producers) not 301 
included in the original 40 strain panel (full details of the isolates are detailed in Table S1). All 302 
isolates were stored in glycerol at -80oC and sub-cultured onto two MHA plates for 18-24h at 303 
37oC prior to each experiment. In each non-HFIM experiment, colonies were suspended in PBS 304 
to MacFarland standard 0.5 (1x108 CFU/mL) and diluted to the target concentration. For HFIM 305 
experiments, bacteria was incubated in MHB until the bacteria entered exponential growth, 306 
and quantified by optical density (600nm) according to a strain specific standard growth curve. 307 
Antimicrobial susceptibility testing. Fosfomycin and amikacin minimum inhibitory 308 
concentrations (MICs) for the panel of representative neonatal sepsis bacterial pathogens were 309 
determined using the EUCAST broth microdilution methodology (43). E. coli ATCC 25922 or S. 310 
aureus ATCC 29213 were used as controls in all experiments. The antibiotic gradient strip assay 311 
method was used for isolates from the hollow fiber experiment. Briefly, an inoculum of the 312 
isolate was made using a suspension of a sweep of colonies into PBS to a McFarland standard of 313 
0.5. A lawn of the inoculum was plated onto a MHA plate and an antibiotic gradient strip (Etest, 314 
Biomerieux, Marcy-l’Étoile, France) placed on the plate, which is subsequently incubated for 18-315 
24h at 37oC before reading. Interpretation of susceptibility was determined using  2020 EUCAST 316 
breakpoints (28). The breakpoint for IV fosfomycin was used for fosfomycin MIC interpretation. 317 
In vitro pharmacodynamic assays. Checkerboard assays were used on selected strains to assess 318 
the pharmacodynamic interaction of the fosfomycin/amikacin combination. Strains were 319 
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selected based on having MICs 32mg/L and >0.0625 mg/L to both fosfomycin and amikacin.  320 
100 L of antimicrobials in sterile distilled water were added to the an 8x8 grid on a 96 well 321 
plate, with concentration gradients created with 1:2 serial dilutions along each axis, with the 322 
final row/column having 0 mg/L of the appropriate drug. The drug concentration range used on 323 
each plate was chosen according to the drug MICs of each strain, with the maximum 324 
concentration of each antimicrobial being 4x MIC for that strain. The inoculum was made up to 325 
1x106 CFU/mL in MHB and quantified using 1:10 serial dilution onto MHA plates. 100l of the 326 
inoculum was added to each well of the prepared checkerboard. The well containing 0 mg/mL 327 
of each drug acted as the positive control; an additional row of blank MHB on the plate acted as 328 
negative control. Plates were incubated 18-24h at 37oC before being read by optical 329 
densitometer (Varioskan, Thermo Fisher) at 600nm. Plates were considered valid if the MIC on 330 
the monotherapy rows of the checkerboard were within 1 dilution of previously determined 331 
MICs, the negative controls had no growth, and the prepared inoculum was within 6-14 x 105 332 
CFU/mL. 333 
Raw optical densitometer (OD) readings were normalised to that of the positive control. The 334 
readouts were then modelled using Greco’s model of drug synergy (15) using ADAPT 5 (44), 335 
with determination of , with confidence intervals calculated using standard error of the model 336 
outputs. Meta-analysis was performed on the output of the combination using the R package 337 
‘Metafor’ (45). 338 
Hollow Fiber Infection Model. The hollow fiber infection model (HFIM) is a well-established 339 
dynamic model stimulating the pharmacodynamic effect of antimicrobials with physiological 340 
dynamic concentrations  (46). The HFIM method was used largely as described previously (33). 341 
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Briefly, each arm in the HFIM is set up as demonstrated in Fig. S1; monotherapy arms omit the 342 
supplementary compartments. MHB is pumped into the central compartment at a rate set to 343 
simulate a physiological clearance rate for the drug, with all media in the central compartment 344 
above 300 mL removed via an elimination pump. The target simulated half-lives for fosfomycin 345 
and amikacin were 5.1 and 7 hours respectively. The neonatal half-life of fosfomycin was 346 
determined from then unpublished data from the NeoFosfo trial (23). The neonatal half-life of 347 
amikacin was sourced from the SPC (47) and confirmed with other published neonatal clinical 348 
PK data (48–52)  To account for the difference in clearance between fosfomycin and amikacin, 349 
supplementary compartments were set up according the principles laid out by Blaser (53). 350 
Throughout the HFIM experiments, inoculum concentrations were determined by serial dilution 351 
1:10. A total of 10L of each dilution was pipetted onto MHA plates; one drug-free and two 352 
containing either fosfomycin or amikacin. An additional 100L of the original inoculum was 353 
plated onto a drug-free MHA plate to lower the limit of detection for total bacterial 354 
quantification (i.e. to 10 CFU/mL). Plates were then incubated at 37oC for 18-24 hr for drug free 355 
plates, and 42-48 hr for drug-containing plates. After incubation, colonies were counted for at 356 
least two dilutions and the CFU/mL of the original inoculum was calculated. 357 
Preliminary monotherapy experiments were performed with the ESBL-producing ST195 E. coli 358 
strain (fosfomycin MIC 1mg/L, amikacin MIC 4 mg/L; supplied by the University of Birmingham) 359 
(19). PK and PD outputs of these experiments were modelled using Pmetrics (54) and 360 
parameters simulated using ADAPT (44) to determine the fosfomycin and amikacin doses 361 
required to achieve EC20, EC50 and EC80 in terms of bactericidal effect within the HFIM. A 16-arm 362 
HFIM experiment was performed using a 4x4 dosing matrix using these three doses and no 363 
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dose for both antibiotics in combination. The experiment was run over 96 hours, with a target 364 
initial inoculum of 1x106 CFU/mL of ST195 inoculated into the hollow fiber cartridges. A dose of 365 
fosfomycin corresponding to the EC20, EC50 and EC80 was administered every 12 hours to the 366 
primary central compartment only; an amikacin dose achieving the EC20, EC50 and EC80 was 367 
administered to the primary and supplementary central compartments every 24 hours. 368 
PK samples were taken for bioanalysis at four timepoints in dosing windows in days 1 and 3 of 369 
the experiment. Samples of inoculum were taken from each hollow fiber cartridge at 4 370 
timepoints during the first 24h, then once daily before administration of dose until the 96h 371 
timepoint. Each sample was prepared and plated onto drug-free square agar plates and 372 
fosfomycin- and amikacin- containing plates, as described above. MICs from any viable colonies 373 
from each arm on the final timepoint were determined via antibiotic gradient strip assay . 374 
Further HFIM experiments were performed assessing the effect of clinically relevant fosfomycin 375 
and amikacin doses leading to neonatal-like pharmacokinetic profile alone and in combination 376 
against a variety of bacteria with different fosfomycin and amikacin MICs. PK profiles of 377 
fosfomycin and amikacin were designed to have half-lives of 5.1 and 7 hours, with Cmax values 378 
of 250mg/L and 40mg/L respectively. These were determined from the sources used to 379 
determine the half-life, as described earlier. Nine parallel experiments were performed using 380 
nine Gram-negative strains with a wide distribution of fosfomycin and amikacin MICs (Table 2). 381 
Each individual experiment consisted of 4 arms; monotherapy arms for both fosfomycin and 382 
amikacin, a combination therapy arm, and an untreated control. As this experiment aimed to 383 
replicate clinically relevant drug exposures in neonates, each experiment lasted 7 days to 384 
reflect the typical treatment course of neonatal sepsis. Four PK samples were taken in each of 385 
 on M





















three dose intervals distributed evenly throughout the experiment. Four inoculum samples 386 
were taken on day 1, and once every 24h thereafter. These samples were quantified on drug-387 
free, fosfomycin-, and amikacin-containing square MHA plates. MICs from any viable colonies 388 
from each arm on the final timepoint were determined via antibiotic gradient strip assay. 389 
Amikacin Bioanalysis. The internal standard, [2H5] amikacin (Alsachim, Illkirch-Graffenstaden, 390 
France) was prepared in acetonitrile plus 5% trichloroacetic acid (TCA) (25 mg/L, Fisher 391 
Scientific, UK) and 150 L was added to a 96-well protein precipitation plate (Phenomenex, 392 
Cheshire, UK).  Fifty L each of samples, blanks, calibrators in the range 0.5 – 50 mg/L and 393 
quality controls (0.75, 7.5 and 37.5 mg/L) were mixed with the internal standard on an orbital 394 
shaker.  Liquid was drawn through the protein precipitation plate into a collection plate using a 395 
positive pressure manifold.  Samples were evaporated under nitrogen (40 L/min) followed by 396 
reconstitution in water (Fisher Scientific, UK) and 0.1% heptafluorobutyric acid [Sigma-Aldrich, 397 
UK] and mixed using an orbital shaker prior to analysis by LC-MS-MS. 398 
LC-MS-MS analysis was performed using an Agilent 1290 Infinity HPLC coupled to an Agilent 399 
6420 triple quadrupole mass spectrometer fitted with an electrospray source controlled using 400 
Agilent MassHunter Data Acquisition software (Ver B.06.00).  Analytes were injected (5 L) onto 401 
a Discovery® HS C18 HPLC Column (2.1 mm x 50 mm, 3 µm, 50°C) and separated over a 3.5 min. 402 
gradient using a mixture of solvents A (LC-MS grade water with 0.1% (v/v) heptafluorobutyric 403 
acid) and B (HPLC grade acetonitrile with 0.1% (v/v) heptafluorobutyric acid). Separations were 404 
performed by applying a linear gradient of 2% to 98% solvent B over 3 mins at 0.5 mL/min 405 
followed by an equilibration step (0.5 mins at 2% solvent B).  406 
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The mass spectrometer was operated in positive ion mode using a Multiple Reaction 407 
Monitoring (MRM) method with the specified mass transitions and collision energies: amikacin 408 
586.4 > 163.2 (Ce 30 ev) and [2H5] amikacin 591.3 > 163.2 (Ce 30 ev). Mass spectrometry 409 
readouts were processed using Agilent Mass Hunter Quantitative Analysis (Ver B.05.02). 410 
Prior to sample analysis, the analytical method was validated to assess recovery and matrix 411 
effects, inter- and intra-day accuracy and precision, carryover, dilution integrity, stability in 412 
matrix (4 hours at room temperature and 3 freeze thaw cycles) and processed sample stability 413 
(reinjection of extracts after 24hrs).  The average recovery from matrix was 75.3%.  The limit of 414 
quantification (LLQ) was defined as 0.5 mg/L and the limit of detection (LOD) 0.25 mg/L.  The 415 
inter- and intra-day %CV on the three QC levels ranged from 2.5% – 5.7% and 2.9% – 6.41% 416 
respectively.  The analyte was found to be stable in all conditions described above. 417 
Fosfomycin Bioanalysis. The internal standard, Ethyl Phosphonic acid (Sigma Aldrich, UK) was 418 
prepared in acetonitrile (5 mg/L, Fisher Scientific UK) and 200 L was added to a 96-well protein 419 
precipitation plate (Phenomenex, Cheshire, UK).  Fifty L each of samples, blanks, calibrators in 420 
the range 1 – 500 mg/L and quality controls (3.5, 35 and 350 mg/L) were mixed with the 421 
internal standard on an orbital shaker.  Liquid was drawn through the protein precipitation 422 
plate into a collection plate using a positive pressure manifold with water and 2mM Ammonium 423 
acetate (150 L) added to each well, before sealing and mixing on an orbital shaker.  424 
LC-MS-MS analysis was carried out using the same technical setup as described above.  425 
Analytes were injected (5 L) onto an Agilent ZORBAX RRHD HILIC Plus 95Å Column (2.1 mm x 426 
50 mm, 1.8 µm, 40°C) and separated over a 3.5 min. gradient using a mixture of solvents A (LC-427 
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MS grade water with 2mM (v/v) ammonium acetate) and B (HPLC grade acetonitrile). 428 
Separations were performed by applying a linear gradient of 100% to 0% solvent B over 2 mins 429 
at 0.4 mL/min followed by an equilibration step (1.5 mins at 100% solvent B).  430 
The mass spectrometer was operated in negative ion mode using a Multiple Reaction 431 
Monitoring (MRM) method with the specified mass transitions and collision energies: 432 
fosfomycin 137.1 > 79.0 (Ce 20 ev) and EPA 109.1 > 79.0 (Ce 20 ev). Mass spectrometry 433 
readouts were processed as described above. 434 
This fosfomycin analytical method underwent the same validation process as the amikacin 435 
method described above. The average recovery from matrix was 80.9%.  The LLQ was defined 436 
as 1 mg/L and the LOD 0.5 mg/L.  The inter and intra day %CV on the three QC levels ranged 437 
from 6.5% – 8.1% and 4.7% – 6.9% respectively.  The analyte was found to be stable in all 438 
conditions described above. 439 
Modelling. Population PK models were constructed using the pharmacokinetic and 440 
pharmacodynamic outputs of the hollow fiber experiments using the population PK program 441 
Pmetrics using a nonparametric adaptive grid NPAG estimation routine (54). The structural 442 
model was based on Greco’s models of pharmacological synergy (15) (described in full in Text 443 
S1, Supplementary Materials). 444 
Monte Carlo Simulation. A neonatal model for fosfomycin developed from the Neofosfo trial 445 
(23, 55) and previously published neonatal amikacin (56) was used to simulate 446 
fosfomycin/amikacin PK profiles from 10,000 neonates the linPK package in R (https://cran.r-447 
project.org/web/packages/linpk/index.html). The simulated population was based on the 448 
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demographic distribution of neonates in the Neofosfo trial (23) combined with data from an 449 
international multi-centre neonatal observational trial (24). From the simulated PK profiles, 450 
individual fAUC0-24h values were calculated from the first 24h. 451 
Data availability: The programs ADAPT and Pmetrics are pubically available, with instructions, 452 
at https://bmsr.usc.edu/software/adapt/ and http://www.lapk.org/pmetrics.php respectively.  453 
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Parameter Mean  Median 95% Credibility 
interval 
V1 (L) 0.459 0.469 0.416 – 0.5 
V2 (L) 0.359 0.312 0.306 – 0.417 
Cl1 (L/h) 0.082 0.077 0.0755 – 0.0967 
Cl2 (L/h) 0.038 0.031 0.0308 – 0.0369 
Kgs 1.320 1.124 1.000 - 1.579 
Kks 2.698 2.922 2.700 - 3.000 
E501s (mg/L) 9.081 6.805 4.417 – 11.260 
E502s (mg/L) 11.674 6.768 4.041 – 17.540 
s 16.288  13.046 3.439 – 29.997 
Kgr1 1.375 1.324 1.239 – 1.329 
Kkr1 2.384 2.221 1.933 – 2.902 
E501r1 (mg/L) 34.554 28.833 28.228 – 42.833 
r1 17.023 20.520 11.021 – 22.068 
Kgr2 1.361 1.367 1.299 – 1.375 
Kkr2 2.325 2.070 1.972 – 2.872 
E502r2 (mg/L) 37.795 39.150 28.819 – 43.860 
r2 19.815 25.227 7.259 – 29.675 
H1s 3.794 4.801 2.726 – 4.996 
 on M





















H2s 3.347 3.923 0.735 – 4.967 
H1r1 2.160 2.488 1.205 – 2.831 
H2r2 2.776 2.913 0.883 – 3.942 
Table 1: Parameter values estimates with 95% credibility interval from HFIM PKPD model. V = 632 
Volume of distribution; C = clearance, Kg = bacterial growth constant; Kk = bacterial kill 633 
constant; E50 = Concentration of drug achieving 50% of efficacy;  = interaction parameter; H = 634 
Hill constant. Parameter suffices are defined as follows; 1 = relating to fosfomycin; 2 = relating 635 
to amikacin; s = relating to wildtype bacterial population; r1 = relating to ‘fosfomycin resistant’ 636 
bacterial population; r2 = relating to ‘amikacin resistant’ bacterial population.  637 
  638 
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Table 2: Details of strains used in HFIM testing physiological pharmacokinetics of 640 








ST195 E. coli CTX-M-14 4 1 




NCTC 13451 E. coli 
CTX-M-15, OXA-1, 
TEM-1, aac6'-lb-cr, 
mph(A), catB4, tet(A), 
dfrA7, aadA5, sulI 
16 4 




























NS 16 128 
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 Amikacin MIC (mg/L) 













 256 91.33% 51.81% 3.43% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 
128 99.42% 91.33% 51.81% 3.43% 0.00% 0.00% 0.00% 0.00% 0.00% 
64 99.97% 99.42% 91.33% 51.81% 3.43% 0.00% 0.00% 0.00% 0.00% 
32 100.00% 99.97% 99.42% 91.33% 51.81% 3.43% 0.00% 0.00% 0.00% 
16 100.00% 100.00% 99.97% 99.42% 91.33% 51.81% 3.43% 0.00% 0.00% 
8 100.00% 100.00% 100.00% 99.97% 99.42% 91.33% 51.81% 3.43% 0.00% 
4 100.00% 100.00% 100.00% 100.00% 99.97% 99.42% 91.33% 51.81% 3.43% 
2 100.00% 100.00% 100.00% 100.00% 100.00% 99.97% 99.42% 91.33% 51.81% 
1 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 99.97% 99.42% 91.33% 
Table 3: Probability of attainment of the target (𝑓𝐴𝑈𝐶𝐹/ 𝑀𝐼𝐶𝐹) ∗ (𝑓𝐴𝑈𝐶𝐴/ 𝑀𝐼𝐶𝐴)  > 2709.5 642 
across a range of amikacin and fosfomycin MICs using 10,000 Monte Carlo simulated neonatal 643 
amikacin and fosfomycin fAUCs. Grey shading denotes MIC combinations with probability of 644 
target attainment < 95%.  645 
 on M





















Figures  646 
 647 
Figure 1– Modelled output for checkerboard assays to three antimicrobial combinations against 648 
16 isolates, with a combined total statistic for each combination.  is the interaction parameter 649 
in the Greco model indicating the level of synergy. A confidence interval (CI) >0 indicates 650 
presence of synergy; CI <0 indicates antagonism; a CI containing 0 indicates no interaction with 651 
additive effects only.  and p values for combined statistic are given below the figures. I2 652 
represents the heterogeneity in effect between individual strains.   653 
 on M
























Figure 2 – Pharmacodynamic output of 16-arm fosfomycin/amikacin combination HFIM 657 
experiment, with labelled fAUC0-24 for each arm. Grey cross in arm 15 was a real data-point in 658 
the initial experiment but was not reproducible in repeat experiments. It is demonstrated here 659 
for completeness but was not included in the modelling.   660 
 on M






















Figure 3 – Pharmacodynamic relationships of emergence of resistance in relation to modelled 662 
fAUC:MIC ratios for each agent. (A) Increasing fosfomycin fAUC:MIC on a background of fixed 663 
 on M





















Amikacin fAUC:MIC; (B) Increasing amikacin fAUC:MIC on a background of fixed fosfomycin 664 
fAUC:MIC.  665 
 on M























Figure 4 – Summary of pharmacodynamic outputs of fosfomycin/amikacin antimicrobial 668 
combination and monotherapy regimens in HFIM shown by pathogen fosfomycin/amikacin 669 
MICs (A) and fosfomycin/amikacin fAUC:MIC ratio (B). Success is defined by bacterial kill to 670 
sterility at the end of the experiment. 671 
 on M
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